Gene symbol | MAGEA3 | Synonyms | CT1.3, HIP8, HYPD, MAGE3, MAGEA6 | Type of gene | protein-coding |
Chromosome | X | Map location | Xq28 | dbXrefs | |
Gene perturbation-related omics dataset | PerturbAtlas | ||||
Description | MAGE family member A3 |
Gene symbol | MAGEC1 | Synonyms | CT7, CT7.1 | Type of gene | protein-coding |
Chromosome | X | Map location | Xq27.2 | dbXrefs | |
Description | MAGE family member C1 |
Gene symbol | WT1 | Synonyms | AWT1, GUD, NPHS4, WAGR, WIT-2, WT-1, WT33 | Type of gene | protein-coding |
Chromosome | 11 | Map location | 11p13 | dbXrefs | |
Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
Description | WT1 transcription factor |
GTO ID | GTC0191 |
Trial ID | NCT01995708 |
Disease | Myeloma |
Altered gene | MAGE-C1|MAGE-A3|WT1 |
Therapeutic/Target gene | Therapeutic gene |
Therapy | mRNA vaccine |
Treatment | LC Vaccine |
Phase | Phase1 |
Recruitment status | Completed |
Title | A Phase I Trial of Vaccination With CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation |
Year | 2014 |
Country | United States |
Company sponsor | Memorial Sloan Kettering Cancer Center |
Other ID(s) | 13-009 |
Vector information | |||
|
Cohort1: LC vaccines | |||||||||||||||
|
|||||||||||||||
Cohort2: Standard of care | |||||||||||||||
|